Iron-Deficiency Anemia Clinical Trial
Official title:
Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy
Multicentre, randomised, controlled, 2-arm open-label prospective pilot study to evaluate efficacy and safety of ferric carboxymaltose (FCM) in treatment of anaemia in subjects with multiple myeloma (MM) initiating chemotherapy. The subjects will be screened for eligibility within 4 weeks prior to inclusion and randomised to receive intravenous infusions of FCM or standard care (the subjects may be treated according to the local institutional practice if requiring symptomatic management of anaemia). Thereafter the visits are scheduled at Weeks 0, 2, 4, 6 and 8.
Patients will be randomised into two groups. One will receive active FCM treatment and the other group will receive local standard of care. Active treatment group: Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the first scheduled chemotherapy cycle or within 24 hours before or after receiving chemotherapy. In subjects of weight ≤66 kg, the first dose (500 mg) will be administered on the day of the first scheduled chemotherapy cycle and the second dose (500 mg) on the next study visit. Standard of care group: Subjects will be treated according to the local institutional practice if requiring management of symptomatic anaemia. Intravenous iron should only be used to treat absolute iron deficiency (as defined as ferritin less than the lower limit of normal based on the test reference ranges). Patients with absolute iron deficiency are not eligible for inclusion to the study. Rescue medication to manage anaemia is permitted in both arms at the discretion of the treating physician and/or per institutional practice. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04949165 -
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
|
N/A | |
Active, not recruiting |
NCT02541708 -
IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania
|
Phase 3 | |
Completed |
NCT01942460 -
Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients
|
Phase 4 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Completed |
NCT00810030 -
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
|
Phase 3 | |
Completed |
NCT00298051 -
Umbilical Cord Clamping and Infant Iron Status
|
N/A | |
Completed |
NCT01135576 -
Iron Fortified Beverages and Application in Women Predisposed to Anemia
|
N/A | |
Withdrawn |
NCT04320966 -
Neurovascular Complications and White Matter Damage in Acquired Anemias
|
||
Completed |
NCT01101399 -
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
|
Phase 3 | |
Completed |
NCT05240677 -
Endoscopy in CKD With Iron Deficiency Anemia
|
N/A | |
Recruiting |
NCT02487719 -
Different Iron Supplements for Prevention of Anemia in Pregnancy
|
Phase 4 | |
Recruiting |
NCT03232554 -
Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia
|
Phase 2 | |
Terminated |
NCT02341300 -
Use of Cast Iron Pots to Improve Maternal Anemia
|
N/A | |
Completed |
NCT04318405 -
Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE).
|
||
Completed |
NCT02998697 -
Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03411590 -
The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers
|
N/A | |
Completed |
NCT05365308 -
EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia
|
N/A | |
Recruiting |
NCT01071759 -
Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes
|
N/A | |
Terminated |
NCT00882414 -
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)
|
Phase 2 | |
Completed |
NCT02968368 -
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
|
Phase 3 |